Kiromic BioPharma, Inc.
11 articles about Kiromic BioPharma, Inc.
-
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
9/13/2023
Kiromic BioPharma announces that on September 12, 2023 it received formal notice from the NASDAQ Stock Market that the Company’s common stock has been suspended from trading on the Nasdaq Capital Market effective September 14, 2023, due to failure to demonstrate compliance with Listing Rule 5550.
-
Kiromic BioPharma Welcomes Two New Directors to its Board - July 24, 2023
7/24/2023
Kiromic BioPharma, Inc., a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors.
-
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
5/1/2023
Kiromic BioPharma, Inc. today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
-
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
4/3/2023
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC).
-
Kiromic BioPharma Announces Reverse Stock Split - March 10, 2023
3/10/2023
Kiromic BioPharma, Inc. announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time , March 10, 2023.
-
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
2/28/2023
Kiromic BioPharma Reports Favorable Deltacel ™ Preclinical Pharmacology Results.
-
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
2/23/2023
Kiromic BioPharma, Inc. announces that Institutional Shareholder Services and Glass Lewis & Co., two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all three proposals at the Company’s Special Meeting of Stockholders being held March 7, 2023.
-
Kiromic BioPharma CEO Issues Letter to Stockholders
2/16/2023
Kiromic BioPharma, Inc., a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, issued the following letter to stockholders from its CEO Pietro Bersani.
-
Kiromic BioPharma Arranges Up to $10 Million Financing
10/27/2022
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD.
-
The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.
-
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
10/6/2022
Kiromic BioPharma, Inc. announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.